Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy
Hyung Woo Kim, Ju Sang Kim
Tuberc Respir Dis. 2018;81(1):6-12.   Published online 2017 Dec 15     DOI: https://doi.org/10.4046/trd.2017.0052
Citations to this article as recorded by Crossref logo
Latent tuberculosis infection: recent progress and challenges in South Korea
Doosoo Jeon
The Korean Journal of Internal Medicine.2020; 35(2): 269.     CrossRef
Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea
Jinsoo Min, Hyung Woo Kim, Helen R Stagg, Marc Lipman, Molebogeng X Rangaka, Jun-Pyo Myong, Hyeon Woo Yim, Jeong Uk Lim, Yunhee Lee, Hyeon-Kyoung Koo, Sung-Soon Lee, Jae Seuk Park, Kyung Sook Cho, Ju Sang Kim
BMJ Open.2020; 10(2): e034098.     CrossRef
Anti-tubercular activity of novel class of spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids
Natarajan Arumugam, Abdulrahman I. Almansour, Raju Suresh Kumar, Shatha Ibrahim Alaqeel, Vagolu Siva Krishna, Dharmarajan Sriram
Bioorganic Chemistry.2020; 99: 103799.     CrossRef
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Ewan A Langan, Victoria Graetz, Judith Allerheiligen, Detlef Zillikens, Jan Rupp, Patrick Terheyden
The Lancet Oncology.2020; 21(1): e55.     CrossRef
Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues
Nonkululeko H. Zuma, Frans J. Smit, Ronnett Seldon, Janine Aucamp, Audrey Jordaan, Digby F. Warner, David D. N'Da
Bioorganic Chemistry.2020; 96: 103587.     CrossRef
Mini-open anterior approach focal cleaning combined with posterior internal fixation for thoracolumbar tuberculosis: Follow-up of 149 cases
Dexin Hu, Jun Fei, Genjun Chen, Yongjie Yu, Zhen Lai
Asian Journal of Surgery.2020; 43(1): 78.     CrossRef
Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection
Ock-Hwa Kim, Kyung-Wook Jo, Shinhee Park, Yong-Ha Jo, Mi-Na Kim, Heungsup Sung, Tae Sun Shim, Katalin Andrea Wilkinson
PLOS ONE.2020; 15(6): e0234700.     CrossRef
A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients
Andrea Sosa-Moreno, Masahiro Narita, Christopher Spitters, Michelle Swetky, Sara Podczervinski, Margaret L Lind, Leona Holmberg, Catherine Liu, Raleigh Edelstein, Steven A Pergam
Open Forum Infectious Diseases.2020;[Epub]     CrossRef
Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis
Seon-Sook Han, Su Jin Lee, Jae-Joon Yim, Jin Hwa Song, Eun Hye Lee, Young Ae Kang, Lei Gao
PLOS ONE.2019; 14(9): e0222810.     CrossRef
Factors Influencing the Diagnosis and Treatment of Latent Tuberculosis among Contacts in Congregated Settings in Korea
Ahreum Kim, Minhyeok Choi
Journal of Korean Medical Science.2019;[Epub]     CrossRef
Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area
Diana Maria de Almeida Lopes, Valéria Goes Ferreira Pinheiro, Helena Serra Azul Monteiro
Jornal Brasileiro de Pneumologia.2019;[Epub]     CrossRef
Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis
Marie Nancy Séraphin, HsiaoChu Hsu, Helena J. Chapman, Joanne L. de Andrade Bezerra, Lori Johnston, Yang Yang, Michael Lauzardo
BMC Public Health.2019;[Epub]     CrossRef
Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers
Kyung-Wook Jo, Ju Sang Kim, Hyouk-Soo Kwon, Yea Eun Park, Ja Young Kim, Min Jee Hong, Tae Sun Shim
Respiratory Medicine.2019; 158: 42.     CrossRef
Towards optimal treatment for latent Mycobacterium tuberculosis infection
Ibrahim Abubakar, Jeremiah Chakaya, Markus Maeurer, Alimuddin Zumla
The Lancet Respiratory Medicine.2019; 7(3): 195.     CrossRef
Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis
Wallace J. Reis, Ícaro A.O. Bozzi, Matheus F. Ribeiro, Priscila C.B. Halicki, Laís A. Ferreira, Pedro E. Almeida da Silva, Daniela F. Ramos, Carlos A. de Simone, Eufrânio N. da Silva Júnior
Bioorganic & Medicinal Chemistry.2019; 27(18): 4143.     CrossRef
Demanding an end to tuberculosis
Justine Fargher, Anja Reuter, Jennifer Furin
Current Opinion in HIV and AIDS.2019; 14(1): 21.     CrossRef
Quality of life of patients on treatment for latent tuberculosis infection: a mixed-method study in Stockholm, Sweden
Jad Shedrawy, Lena Jansson, Isac Röhl, Asli Kulane, Judith Bruchfeld, Knut Lönnroth
Health and Quality of Life Outcomes.2019;[Epub]     CrossRef
Nutritional Adequacy and Latent Tuberculosis Infection in End-Stage Renal Disease Patients
Seung Don Baek, Soomin Jeung, Jae-Young Kang
Nutrients.2019; 11(10): 2299.     CrossRef
Diagnosis and treatment of latent tuberculosis infection
Jinsoo Min, Ju Sang Kim
Journal of the Korean Medical Association.2019; 62(1): 11.     CrossRef
Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
Eun Hye Lee, Seung Hyun Yong, Ah Young Leem, Sang Hoon Lee, Song Yee Kim, Kyung Soo Chung, Ji Ye Jung, Moo Suk Park, Young Sam Kim, Joon Chang, Young Ae Kang
Open Forum Infectious Diseases.2019;[Epub]     CrossRef
The Comparison Study between Tuberculin Skin Test and Interferon Gamma Release Assay in BCG-Vaccinated Healthy Donors
Yoon-Sung Choi, Sunghyun Kim
Biomedical Science Letters.2018; 24(2): 138.     CrossRef
PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA
ZH. K. RАKISHEVА, G. S. BАLАSАNYANTS, А. S. АKISHEVА, А. B. TSEPKE, N. S. SOLOVIEVА
TUBERCULOSIS AND LUNG DISEASES.2018; 96(8): 50.     CrossRef